supp.fit

St. John's Wort: study protocols

79 study groups say how much St. John's Wort participants took a day. These are the doses the studies gave. They are not a recommendation.

St. John's Wort: what the research found →

Dose per serving from products

232 products in our catalogue print how much St. John's Wort a serving holds.

Most common: 100 mg to 250 mg, 47% of 232 products.

Dose per servingProducts
25 mg or less
10
25 mg to 50 mg
24
50 mg to 100 mg
19
100 mg to 250 mg
108
250 mg to 500 mg
38
500 mg to 1 g
30
over 1 g
3

Dose per serving from research

79 study groups in 59 studies say how much St. John's Wort participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 67% of 79 study groups.

Daily doseStudy groups
50 mg or less
4
50 mg to 100 mg
1
100 mg to 250 mg
1
250 mg to 500 mg
7
500 mg to 1 g
53
1 g to 2.5 g
9
over 2.5 g
4

Commonly used together

2 of 79 study groups took St. John's Wort with something else, but nothing that 3 or more different studies gave.

79 study groups

Study
Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial
2008 · WS 5570 · Adults with recurrent moderate major depression who had recovered after an acute episode; at least three previous episodes in five years
900 mg26 weeks282
Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial
2011 · Hypericum extract STW 3-VI group · Adults with mild to moderate depression who responded to treatment for an episode of moderate depression
900 mg6 weeks54
Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial
2002 · WS 5570 · Adult male and female outpatients with mild to moderate major depression, single or recurrent episode, meeting DSM-IV criteria
900 mg6 weeks186
The Ham D(6) is more homogenous and as sensitive as the Ham D(17)
2007 · hypericum extract · Patients with single or recurrent depression according to DSM-IV
900 mg6 weeks186
Comparison of St John's wort and imipramine for treating depression: randomised controlled trial
2000 · hypericum group · Outpatients with mild to moderate depression; age and sex not specified
500 mg6 weeks157
Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort
2001 · Ze 117 St. John's wort · Outpatients with mild to moderate depressive episodes, ICD-10 F32.0 or F32.1; age and sex not reported
500 mg6 weeks126
Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline
2005 · hypericum group · Patients with moderate depressive disorder
612 mg24 weeks123
Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
2006 · WS 5570 600 mg/day · Men and women aged 18–65 with a mild or moderate major depressive episode and baseline HAM-D score ≥18
600 mg6 weeks123
Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode
2007 · WS 5570 600 mg/day · Adults with mild to moderate major depression who had recovered with acute treatment and had a HAMD total score decrease of at least 50%.
600 mg120 days69
Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients
1994 · LI 160 group · Adults with depressive disorders treated as outpatients; age and sex not reported
900 mg6 weeks67
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
2005 · St John's wort group · Adults with major depressive disorder diagnosed by Structured Clinical Interview for DSM-IV; mean age 37.3 years; 57% women across the trial
900 mg12 weeks45
Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients
1994 · active group · Outpatients with mild depression of short duration; age and sex not reported
900 mg4 weeks42
Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial
2001 · WS 5572 · Adults with mild to moderate major depressive disorder
900 mg6 weeks37
The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial
2010 · Hypericum perforatum · Women aged 18–45 years with prospectively diagnosed mild premenstrual syndrome
900 mg—36
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study
2006 · WS 5570 900 mg/d · Adult out-patients with moderate to severe major depression who responded to 6 weeks of acute treatment
900 mg16 weeks33
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial
2003 · cycle A · healthy females
600 mg—17
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial
2003 · cycle B · healthy females
900 mg—17
Hypericum in the treatment of seasonal affective disorders
1994 · Hypericum with bright light condition · Patients with major depression with seasonal pattern (seasonal affective disorder); age and sex not reported
900 mg4 weeks10
Hypericum in the treatment of seasonal affective disorders
1994 · Hypericum with dim light condition · Patients with major depression with seasonal pattern (seasonal affective disorder); age and sex not reported
900 mg4 weeks10
Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine
1999 · LoHyp-57 (St. John's wort extract) · Elderly out-patients with mild or moderate depressive episodes
800 mg6 weeks—
St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial
2002 · LI 160 (Hypericum) group · Outpatients with somatization disorder, undifferentiated somatoform disorder, or somatoform autonomic dysfunction; age and sex not reported
600 mg6 weeks—
Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial
2004 · St. John's wort group · Outpatients with somatization disorder, undifferentiated somatoform disorder, or somatoform autonomic dysfunction, without major depression; age and sex not reported
600 mg6 weeks—
Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo
2005 · Hypericum extract (HE LI 160) · Patients with major depressive disorder and reversed vegetative signs; age and sex not reported
900 mg12 weeks—
Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients
2005 · Hypericum LI 160 · Outpatients with mild to moderate major depression (DSM-IV); age and sex not reported
900 mg4 weeks—
Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial
2004 · Hypericum extract group · Outpatients with moderate depressive disorders and HAMD-17 scores of 20 to 24; adults, sex and age range not specified
900 mg6 weeks—
Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine
2005 · Hypericum group · Adults with acute moderate to severe major depression; age range not specified
900 mg6 weeks—
The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study
2006 · lower-dose Hypericum · Adults aged 25–70 with minor depressive symptoms, mild or moderately severe depressive episodes, or dysthymia
810 mg6 weeks—
The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study
2006 · higher-dose Hypericum · Adults aged 25–70 with minor depressive symptoms, mild or moderately severe depressive episodes, or dysthymia
810 mg6 weeks—
Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study
2006 · hypericum extract STW3-VI · Outpatients with moderate depression; age and sex not reported
900 mg6 weeks—
St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial
2010 · LI160 · Patients with mild or moderate major depression and vegetative features of atypical depression; age and sex not specified
600 mg8 weeks—
The acute effect of Hypericum perforatum on short-term memory in healthy adults
2019 · Remotiv 500 · Healthy student adults; 33 of the 82 participants were women
500 mg1 day—
Hypericum treatment of mild depressions with somatic symptoms
1994 · Hypericum extract LI 160 · Patients with depression with somatic symptoms; age and sex not reported
900 mg4 weeks—
Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study
1994 · hypericum extract · Patients with depression (ICD-10, F 32.1); age and sex not specified
900 mg4 weeks—
LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial
1997 · LI 160 group · Mildly to moderately depressed outpatients; age and sex not stated
900 mg6 weeks—
St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy
1998 · Hypericum extract WS 5573 · Male and female outpatients with mild or moderate depression according to DSM-IV criteria
900 mg6 weeks—
St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy
1998 · Hypericum extract WS 5572 · Male and female outpatients with mild or moderate depression according to DSM-IV criteria
900 mg6 weeks—
Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
2006 · WS 5570 1200 mg/day · Men and women aged 18–65 with a mild or moderate major depressive episode and baseline HAM-D score ≥18
1.2 g6 weeks127
Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode
2007 · WS 5570 1200 mg/day · Adults with mild to moderate major depression who had recovered with acute treatment and had a HAMD total score decrease of at least 50%.
1.2 g120 days68
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study
2006 · WS 5570 1800 mg/d · Adult out-patients with moderate to severe major depression who responded to 6 weeks of acute treatment
1.8 g16 weeks38
Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks
1999 · Hypericum extract · Adults with moderate depression, 66 men and 197 women; age range not reported
1.05 g8 weeks—
The acute effect of Hypericum perforatum on short-term memory in healthy adults
2019 · Remotiv 250 · Healthy student adults; 33 of the 82 participants were women
250 mg1 day—
Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10
1997 · LI 160 group · Patients with severe depressive episodes according to ICD-10; age and sex not reported
1.8 g6 weeks—
Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin
2007 · Movina · Adults with hypercholesterolemia taking a stable dose of simvastatin
600 mg4 weeks24
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia
2007 · Movina · Patients with hypercholesterolemia taking a stable dose of atorvastatin
600 mg4 weeks16
A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L
1999 · 1 mg group · Adult outpatients with mild to moderate depression
1 mg6 weeks119
A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L
1999 · 0.33 mg group · Adult outpatients with mild to moderate depression
330 mcg6 weeks115
A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L
1999 · 0.17 mg group · Adult outpatients with mild to moderate depression
170 mcg6 weeks114
Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial
2009 · St. John's wort group · Symptomatic perimenopausal women aged 40 to 65 years experiencing at least three hot flashes per day
2.7 g90 days—
Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans
1997 · Multiple-dose hypericum extract · Volunteers; sex, age and health condition not reported
1.81 g15 days50
Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG
1998 · 0.5% hyperforin extract · Healthy volunteers aged 18–35 years
900 mg8 days18
Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG
1998 · 5.0% hyperforin extract · Healthy volunteers aged 18–35 years
900 mg8 days18
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin
2001 · St John's Wort treatment · Healthy adult men
900 mg2 weeks16
Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans
2004 · St John's wort · Healthy adults, 11 men and 5 women; mean age 31 years
900 mg7 days16
St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial)
2013 · SJW · Patients with stable angina who were non-responders to clopidogrel after percutaneous coronary intervention
900 mg2 weeks15
Drug interaction between St John's Wort and quazepam
2004 · St John's Wort · healthy subjects; age and sex not specified
900 mg2 weeks13
St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole
2004 · St John's wort · Healthy adult men aged not reported, with CYP2C19 wild-type or variant genotypes
900 mg2 weeks12
The influence of St John's Wort on CYP2C19 activity with respect to genotype
2004 · St. John's wort · Healthy adult men, including CYP2C19 extensive and poor metabolizers
900 mg2 weeks12
Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba
2005 · St. John’s wort supplementation · Healthy elderly adults, 67 ± 5.2 years; 6 men and 6 women
900 mg4 weeks12
The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity
2011 · St. John's Wort, hyporesponsive volunteers · Adults identified as clopidogrel-hyporesponsive volunteers; age and sex not stated
900 mg2 weeks10
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol
2007 · St. John’s wort (SJW) · Study subjects; age, sex, and health condition not specified
900 mg12 days9
Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers
2001 · 600 mg WS 5570 · 12 physically and mentally healthy male volunteers
600 mg1 day—
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin
2004 · Low-dose Hypericum powder, 0.5 g · Healthy volunteers
500 mg2 weeks—
Effects of Hypericum extract (LI160) on the change of auditory evoked potentials by cortisol administration
2004 · LI160 · 19 healthy subjects; age and sex not reported
600 mg2 weeks—
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction
2004 · Low-HYF SJW treatment · 10 renal transplant patients taking regular cyclosporine; age and sex not reported
900 mg2 weeks—
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction
2004 · High-HYF SJW treatment · 10 renal transplant patients taking regular cyclosporine; age and sex not reported
900 mg2 weeks—
Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity
2010 · coadministration of ritonavir and St John's wort · Adults; sex and health condition not specified
900 mg2 weeks—
St Johns wort increases expression of P-glycoprotein: implications for drug interactions
2002 · SJW · Healthy volunteers
1.8 g16 days15
Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology
2000 · Soft gelatin formulation · 12 healthy adults, six males and six females
300 mg1 day12
Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology
2000 · Hard gelatin capsule formulation · 12 healthy adults, six males and six females
300 mg1 day12
Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers
2001 · 300 mg WS 5570 · 12 physically and mentally healthy male volunteers
300 mg1 day—
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin
2004 · Low-dose Hypericum powder, 1 g · Healthy volunteers
1 g2 weeks—
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin
2004 · 2 g Hypericum powder without hyperforin · Healthy volunteers
2 g2 weeks—
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin
2004 · 4 g Hypericum powder with comparable hyperforin content · Healthy volunteers
4 g2 weeks—
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin
2004 · 2 g Hypericum powder with half the hyperforin content · Healthy volunteers
2 g2 weeks—
The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose
2006 · LI 160 · Healthy adult men
41 mg2 weeks—
The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose
2006 · SJW powder tablets, HYF 12 mg/day · Healthy adult men
2.7 g2 weeks—
The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose
2006 · SJW powder tablets almost devoid of HYF · Healthy adult men
2.7 g2 weeks—
Early effect of NEURAPAS® balance on current source density (CSD) of human EEG
2011 · NEURAPAS® balance (verum) · Healthy adult volunteers, 8 men and 8 women, mean ages about 47–49 years
60 mg1 day16
The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men
2002 · St John's wort extract · Healthy men; age not reported
765 mg2 weeks12